Ilić D, Cvetković M, Blažević-Kamenov N, Tasić-Kostov M. Topical spironolactone in a natural non-ionic emulsifier based vehicle - a safety assessment, Skin and Formulation. In: 5th Symposium & 17th Skin Forum, Book of abstracts. 2019. p. 57.
2.
Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. Journal of the American Academy of Dermatology. 2018;78(6):1156–63.
3.
Stein-Gold L, Kircik LH, Draelos ZD. Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the two-phase. 3:29-,.
4.
Long-term topical oxymetazoline hydrochloride 1.0% demonstrates sustained and increasing effect in persistent facial erythema of rosacea. Journal of the American Academy of Dermatology. 2018;79(3):AB182.
5.
Topical oxymetazoline hydrochloride 1.0% effectively reduces persistent facial erythema of rosacea on day 1. Journal of the American Academy of Dermatology. 2018;79(3):AB299.
6.
Mashiah J, Kutz A, Rabia SH, Ilan EB, Goldberg I, Sprecher E, et al. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. International Journal of Dermatology. 2017;56(2):148–53.
7.
Wang Y, Zhang X, Yang Y, Zhang J, Yang Y, Lu Y. Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas. The Indian Journal of Pediatrics. 2017;84(6):425–9.
8.
Xu G, Lv R, Zhao Z, Huo R. Topical propranolol for treatment of superficial infantile hemangiomas. Journal of the American Academy of Dermatology. 2012;67(6):1210–3.
9.
Baselga E, Roe E, Coulie J, Muñoz FZ, Boon LM, McCuaig C, et al. Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy. JAMA Dermatology. 2016;152(11):1239.
10.
Bonifazi E, Milano A, Colonna V. Evaluation of safety and efficacy of a galenic preparation of 1% propranolol in 89 cases of cutaneous infantile hemangioma. Eur J Pediat Dermatol. 2013;23:93–104.
11.
Kunzi‐Rapp K. Topical Propranolol Therapy for Infantile Hemangiomas. Pediatric Dermatology. 2012;29(2):154–9.
12.
Tan CE, Itinteang T, Leadbitter P, Marsh R, Tan ST. Low‐dose propranolol regimen for infantile haemangioma. Journal of Paediatrics and Child Health. 2015;51(4):419–24.
13.
Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review. Pediatric Dermatology. 2013;30(2):182–91.
14.
Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Atti MCD, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. European Journal of Pediatrics. 2015;174(7):855–65.
15.
Price A, Rai S, Mcleod RWJ, Birchall JC, Elhassan HA. Topical propranolol for infantile haemangiomas: a systematic review. Journal of the European Academy of Dermatology and Venereology. 2018;32(12):2083–9.
16.
Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. British Journal of Dermatology. 2015;172(1):24–32.
17.
França K, Litewka S. Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies. International Journal of Dermatology. 2019;58(7):788–94.
18.
Corazza M, Strumia R, Lombardi AR, Virgili A. Allergic contact dermatitis from spironolactone. Contact Dermatitis. 1996;35(6):365–6.
19.
Yamamoto A, Ito M. Topical Spironolactone Reduces Sebum Secretion Rates in Young Adults. The Journal of Dermatology. 1996;23(4):243–6.
20.
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-androgenic Therapy Using Oral Spironolactone for Acne Vulgaris in Asians. Aesthetic Plastic Surgery. 2006;30(6):689–94.
21.
Bárány E. 243-250. 2000.
22.
Bárány E, Lindberg M, Lodén M. Unexpected skin barrier influence from nonionic emulsifiers. International Journal of Pharmaceutics. 2000;195(1–2):189–95.
23.
Jaksic I, Lukic M, Malenovic A, Reichl S, Hoffmann C, Müller-Goymann C, et al. Compounding of a topical drug with prospective natural surfactant-stabilized pharmaceutical bases: Physicochemical and in vitro/in vivo characterization – A ketoprofen case study. European Journal of Pharmaceutics and Biopharmaceutics. 2012;80(1):164–75.
24.
Piana M, Silva MA, Trevisan G, Brum TF de, Silva CR, Boligon AA, et al. Antiinflammatory effects of Viola tricolor gel in a model of sunburn in rats and the gel stability study. Journal of Ethnopharmacology. 2013;150(2):458–65.
25.
Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2in treatment of vitiligo. British Journal of Dermatology. 2009;160(4):861–3.
26.
Research and development in the pharmaceutical industry. The Congress of the United States. Congressional Budget Office. 2006;
27.
Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecological Endocrinology. 2007;23(3):142–5.
28.
Chiu HY, Tsai TF. Topical use of systemic drugs in dermatology: A comprehensive review. Journal of the American Academy of Dermatology. 2011;65(5):1048.e1-1048.e22.
29.
Sugarman JH, Fleischer AB, Feldman SR. Off-label prescribing in the treatment of dermatologic disease. Journal of the American Academy of Dermatology. 2002;47(2):217–23.
30.
Kelidari HR, Saeedi M, Akbari J, Morteza-Semnani K, Gill P, Valizadeh H, et al. Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles. Colloids and Surfaces B: Biointerfaces. 2015;128:473–9.
31.
Savić M. Lekovi za dermatološku primenu - klasifikacija i mehanizmi dejstva. Arhiv za farmaciju. 2013;63(2):116–28.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
